Profound Medical Corp. Announces First Quarter 2015 Financial Results of Profound Medical Inc.

TORONTO, ON (July 29, 2015) - Profound Medical Corp. **("Profound")** (TSXV: PRN), a medical device company developing and commercializing a unique, minimally invasive treatment for prostate cancer, today filed its unaudited financial statements for the quarter ended March 31, 2015 of its wholly-owned subsidiary, Profound Medical Inc.

For complete financial results, please see our filings at www.sedar.com.

About Profound Medical Corp.

Profound Medical is a medical device company that has developed a unique and minimally invasive treatment to ablate the prostate gland. Profound's novel technology combines MRI technology with ultrasound thermal energy that is delivered via a transurethral approach. This method of prostate cancer therapy provides highly accurate and precise treatment within the prostate in a short time span, allowing for fast patient recovery. The potential of this technology is currently being demonstrated in clinical trials. For more information, visit profoundmedical.com:

For investor or media inquiries, please contact:

Shameze Rampertab
CFO
Profound Medical Corp.
srampertab@profoundmedical.com
T: 647-476-1350, Ext. 424

Or

Rebecca von Goetz
Senior Marketing & Communications Specialist
Profound Medical Corp.
rvongoetz@profoundmedical.com
T: 647-476-1350, Ext. 426
C: 416.917.8650

*****

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound's technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, *including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.*